Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Semaglutide is a GLP-1 receptor agonist originally developed to treat type 2 diabetes
Increases metabolic support to continue driving weight loss
FOX 13 got this statement from Ozempic drug-maker Novo Nordisk: Ozempic is not approved for chronic weight management
Ozempic dosing schedule: Weeks 1-4: Starting dose 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1 mg once weekly Weeks 13-16: 2 mg once weekly Wegovy Wegovy is FDA-approved for weight management alongside diet and exercise in people with obesity, or people who have overweight and other weight-related health conditions
GLP-1 drugs have been linked to an increased risk of gallbladder problems, such as gallstones and gallbladder inflammation
